Faber Logo
Skip to main content

James R. McGarrah

Co-Founder and Senior Of Counsel 

Jim is a co-founder of Faber and was a principal of the firm from its inception through 2021.

As Senior Of Counsel he continues work on behalf of clients and trains colleagues as part of the firm’s commitment to internal education. Jim’s client projects primarily involve agreements for pre-clinical research programs at companies and non-profit organizations in the life sciences. He advises clients on licenses and research-based transactions intended to enable discovery and development of early-stage novel therapeutic assets and applications for unique technologies. From material transfers, collaborations, and sponsored research to evaluations, options and exclusive development and commercialization licenses, Jim negotiates terms that enable clients to protect their interests in the rapidly advancing life sciences environment.

Over his career, Jim negotiated several unique agreements governing multi-party consortia among industry and non-profit entities, sorting the respective interests and goals for the contributions of each party and providing advice on how to manage the results of joint work. He advises early-stage, venture-backed companies about ways to align mutual research interests with collaborators in the context of the transfer of potentially mission-critical intellectual property rights among academic and corporate organizations.

More about Jim

Counsel

Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceutical Company Limited)
  • Provided legal support for the company’s drug discovery activities and major corporate alliances
  • Negotiated numerous multi-year, sponsored research collaborations with leading academic institutions involving multi-million-dollar research budgets
  • Served as Millennium’s primary counselor on evolving issues in the areas of medical privacy and informed consent requirements for research
  • Legal representative on business development initiatives to license discovery tools and early stage drug candidates, and to establish and conclude product-specific development programs

Counsel

The Institute for Genomic Research (TIGR) (now The J. Craig Venter Institute), one of the first non-profit research centers to incorporate novel technologies in large-scale gene discovery research.
  • Established key parts of the legal framework for its activities with industry and academia
  • Negotiated the terms of early stage research collaborations and agreements covering transfer of materials and confidential information, database access and publication of research results
  • Member of the Institute’s Institutional Review Board; helped assure its compliance with applicable regulations and conditions of federal research grants

  • Exclusive license agreements with University of Michigan, Howard Hughes Medical Institute, Harvard University, Stanford University, Dana-Farber Cancer Institute, Broad Institute, Massachusetts General Hospital, Massachusetts Institute of Technology, Albert Einstein College of Medicine, University of California system, University of Texas system, Dartmouth College, Yale University and Whitehead Institute for Biomedical Research for portfolio companies of leading venture funds
  • Collaboration and sponsorship agreements for staged research projects among multiple universities and a single disease-focused start-up company with federal grant awards under multiple programs
  • Establish core principles and agreement terms for treatment of research results and collaborative research projects for newly established Boston-based non-profit research institute
  • Development of template documents (material transfer, sponsored research and consulting) for multiple start-up companies
  • Exclusive licenses and research agreements with academic centers in Italy, Germany and The Netherlands for U.S. based biopharmaceutical companies
  • Sponsored research, subcontracts and collaborative research and development agreements (CRADAs) with NIH and U.S. defense agencies, universities and companies for clients with novel technologies and funding sources, including government grants and private grant programs

Interested in working with Jim?

Our team is eager to learn more about your project

This site uses cookies. Some provide anonymous analysis of how our website is used and some are essential to make the website work. Other cookies enable personalized services or social media features to be used. By using our website, you agree to the use of cookies. To find out more, please see our Privacy Policy. You can disable cookies at any time by changing your browser settings.